Literature DB >> 15683667

High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours.

Rakesh Jalali1, Ashwini Budrukkar, Rajiv Sarin, Dayananda S Sharma.   

Abstract

BACKGROUND AND
PURPOSE: To report local control and follow up outcome data of high precision conformal radiotherapy in childhood brain tumours.
MATERIALS AND METHODS: Between December 1999 and December 2002, 26 children (17 boys and 9 girls, median age 11.5 years) with incompletely excised or recurrent benign and low-grade brain tumours [13 craniopharyngiomas, 11 low-grade gliomas (LGG) and 2 others] were treated with three-dimensional (3D) conformal radiotherapy (CRT) (12 patients) and stereotactic conformal radiotherapy (SCRT) (14 patients). Gross tumour volume (GTV) included neuro-imaging based visible tumour and/or resected tumour bed. Clinical target volume (CTV) consisted of GTV+ 5 mm margin and planning target volume (PTV) consisted of additional 5 mm margin for CRT and 2 mm for SCRT. Treatment was delivered with 3-9 conformal fixed fields to a median dose of 54 Gy/30 fractions.
RESULTS: The actuarial 2 and 3 year disease free and overall survival was 96 and 100%, respectively (median follow up: 25 months, range 12-47 months). Radiological follow up available in 25 patients revealed complete response in 1, partial regression in 10, stable disease in 13 and progression in 1 patient (within the CTV). One patient with craniopharyngioma on a routine imaging revealed a mild asymptomatic cyst enlargement, which resolved with conservative management. A patient with chiasmatic glioma developed cystic degeneration and hydrocephalus 9 months after SCRT requiring cyst drainage and placement of a ventriculoperitoneal shunt.
CONCLUSION: High-precision conformal techniques delivering irradiation to a computer generated target volume employing 7-10 mm 3D margins beyond the visible tumour and/or resected tumour bed appear to be safe in children with incompletely resected or recurrent benign and low-grade brain tumours, based on these data.

Entities:  

Mesh:

Year:  2005        PMID: 15683667     DOI: 10.1016/j.radonc.2004.09.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease.

Authors:  Sweta Budyal; Anurag R Lila; Rakesh Jalali; Tejpal Gupta; Rajeev Kasliwal; Varsha S Jagtap; Tushar Bandgar; Padmavathy Menon; Nalini S Shah
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

2.  Management of childhood brain tumors: consensus report by the Pediatric Hematology Oncology (PHO) Chapter of Indian Academy of Pediatrics (IAP).

Authors:  Sunil Bhat; Satya Prakash Yadav; Vaishali Suri; Rana Patir; Purna Kurkure; Stewart Kellie; Anupam Sachdeva
Journal:  Indian J Pediatr       Date:  2011-06-22       Impact factor: 1.967

3.  Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy.

Authors:  Rakesh Jalali; Debnarayan Dutta; Rashmi Kamble; Tejpal Gupta; Anusheel Munshi; Rajiv Sarin; Ketayun Dinshaw
Journal:  J Neurooncol       Date:  2008-08-14       Impact factor: 4.130

Review 4.  Radiation-induced brain tumours after central nervous system irradiation in childhood: a review.

Authors:  Benedetta Ludovica Pettorini; Young-Soo Park; Massimo Caldarelli; Luca Massimi; Gianpiero Tamburrini; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2008-04-08       Impact factor: 1.475

5.  Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial.

Authors:  Rakesh Jalali; Tejpal Gupta; Jayant S Goda; Savita Goswami; Nalini Shah; Debnarayan Dutta; Uday Krishna; Jayita Deodhar; Padmavati Menon; Sadhna Kannan; Rajiv Sarin
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.